This study measures the safety and efficacy of repeated low dose MM-120 as treatment for ADHD in adults: a multi-center, randomized, double-blind, placebo-controlled trial.
Status: Recruiting
Start date: 2021-12-17
Phase II
Blinded
52 participants
Interventional
The aim of the present study is to assess the neuronal correlates of alterations in waking consciousness pharmacologically induced by a 5-hydroxytryptamine (HT)2A receptor agonist in healthy subjects using functional magnetic resonance imaging (fMRI).
Status: Completed
Start date: 2014-12-01
Phase I
Open
24 participants
Interventional
96 recently detoxified alcoholics will be randomized to receive either 3 sessions ketamine (0.8 mg/kg IV over 45 minutes) or placebo plus manualised psychological therapy, or 3 sessions of ketamine or placebo plus simple psychoeducation.
Status: Completed
Start date: 2016-10-10
Phase II
Blinded
96 participants
Interventional
The aim of the study is to assess whether SERT inhibition reduces expression of the gene coding for the 5-HT2A receptor and the response to LSD.
Status: Not yet recruiting
Start date: 2022-03-01
Phase I
Blinded
24 participants
Interventional
The purpose of this study is to evaluate the efficacy and safety of switching elderly participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine plus a new oral antidepressant or switching to a new oral antidepressant plus intranasal placebo.
Status: Completed
Start date: 2015-08-20
Phase III
Blinded
139 participants
Interventional
The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) subjects from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine plus a new oral antidepressant or switching to a new oral antidepressant plus intranasal placebo.
Status: Completed
Start date: 2015-08-07
Phase III
Blinded
236 participants
Interventional
The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) participants from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine plus a new oral antidepressant or switching to a new oral antidepressant plus intranasal placebo.
Status: Completed
Start date: 2015-08-10
Phase III
Blinded
346 participants
Interventional
This Phase 2, open-label, non-randomized, 3-cohort study assesses the feasibility and safety of MDMA-assisted group therapy for the treatment of PTSD in veterans
Status: Not yet recruiting
Start date: 2022-06-01
Phase II
Open
18 participants
Interventional
The primary objective of this study is to investigate the serum pharmacokinetics of 5-MeO-DMT and its metabolite, bufotenine in healthy volunteers.
Status: Completed
Start date: 2021-06-21
Phase I
Blinded
46 participants
Interventional
We aim to investigate the effects of a single dose of psilocybin, delivered in the context of pre- and post-dose psychotherapy, on symptoms of depression and burnout suffered by healthcare clinicians as a result of frontline work in the coronavirus disease of 2019 (COVID) pandemic.
Status: Recruiting
Start date: 2021-12-15
Phase I
Blinded
30 participants
Interventional
This study seeks to understand the neural, cognitive and behavioral effects of low doses of psilocybin administered in the form of dried mushroom material (0.5 g of Psilocybe cubensis) consumed in natural settings following a placebo-controlled double-blind experimental design.
Status: Completed
Start date: 2021-01-20
Not Applicable
Open
34 participants
Interventional
This protocol is a Phase 1 open-label study with a primary purpose of evaluating the food effect of a high calorie meal as compared to fasting conditions on the relative bioavailability of oral MDMA capsules in healthy volunteers.
Status: Not yet recruiting
Start date: 2022-04-06
Phase I
Open
12 participants
Interventional
This is a randomized, open-label delayed treatment study to assess the safety and effect of MDMA-assisted therapy in treating 20 participants diagnosed with moderate-to-severe social anxiety disorder (SAD) of the generalized subtype.
Status: Not yet recruiting
Start date: 2022-02-02
Phase II
Blinded
20 participants
Interventional
The primary purpose of this study is to preliminarily estimate the efficacy of psilocybin-facilitated treatment for fibromyalgia.
Status: Not yet recruiting
Start date: 2022-01-01
Phase II
Blinded
30 participants
Interventional
The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy for depression and anxiety in people with Parkinson's disease.
Status: Recruiting
Start date: 2021-08-15
Phase II
Open
10 participants
Interventional
Study DMX-IB 201 is a Phase 1/2a study of ibogaine consisting of an initial single ascending dose escalation stage to determine the maximum tolerated dose (MTD) or treat-to-target dose (TTD) in healthy volunteers.
Status: Recruiting
Start date: 2021-04-1
Phase I
Blinded
110 participants
Interventional
A single centre clinical trial to evaluate the feasibility, safety and efficacy of psilocybin, given under supportive conditions, in a randomised, blinded design in adult participants with treatment resistant major depressive disorder.
Status: Recruiting
Start date: 2020-09-01
Phase II
Blinded
60 participants
Interventional
This is a single-center phase 2a open-label study to assess the efficacy and safety of a dose of psilocybin in subjects with hyperphagia resulting in overeating during both dosing sessions
Status: Not yet recruiting
Start date: 2021-10-11
Phase II
Open
10 participants
Interventional
Working in conjunction with the psychiatrist, LCPC, and Micro Dosing Advisor/On-Boarding Provider this study will shave back the SSRI's and treat with dosing of 1 to 1.5 grams of Plant Medicine Psilocybin every other day for 8 week.
Status: Not yet recruiting
Start date: 2021-06-10
Phase I
Open
30 participants
Interventional
The primary objective of this study is to evaluate the clinical benefit of oral TRP-8802 in concert with psychotherapy to treat chronic pain symptoms in patients with fibromyalgia.
Status: Not yet recruiting
Start date: 2022-05-03
Phase II
Open
20 participants
Interventional
This observational study will allow data to be collected to demonstrate changes in brain activity following administration of standard of care (SOC) ketamine.
Status: Recruiting
Start date: 2021-09-11
Phase II
Open
36 participants
Observational
The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy in people with Bipolar II Disorder.
Status: Not yet recruiting
Start date: 2021-11-11
Phase II
Open
14 participants
Interventional
The overall objective of this study is to develop and pilot test a novel regimen of psilocybin-assisted psychotherapy for demoralization in patients receiving hospice care.
Status: Not yet recruiting
Start date: 2020-11-11
Phase II
Open
15 participants
Interventional
This study is designed to provide information on whether the drug MDMA, combined with Cognitive Processing Therapy (CPT), is safe and helpful for people with Post Traumatic Stress Disorder (PTSD).
Status: Recruiting
Start date: 2021-10-04
Phase II
Open
10 participants
Interventional
The purpose of this study is to see if psilocybin, an investigational drug, is safe and well tolerated. Researchers also want to know if psilocybin can improve symptoms of depression.
Status: Not yet recruiting
Start date: 2021-10-10
Phase II
Open
30 participants
Interventional
This non-interventional study will serve as the long-term follow-up (LTFU) protocol for MDMA-assisted therapy clinical trials and will measure persistence of effectiveness using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) as a measure of PTSD symptom severity
Status: Enrolling by invitation
Start date: 2021-03-01
Not Applicable
Open
400 participants
Observational
The primary objective of this study is to collect insights from first responders and military personnel on their need for, use of, and interest in physical and/or mental health medical marijuana or psychedelic-assisted therapy programs.
Status: Recruiting
Start date: 2021-06-04
Not Applicable
Open
1000 participants
Observational
This is a proof-of-concept randomized clinical trial of psilocybin-enhanced psychotherapy versus treatment-as-usual among individuals being treated for methamphetamine use disorder.
Status: Not yet recruiting
Start date: 2022-01-15
Phase I
Open
30 participants
Interventional
The primary goal of this observational pilot survey is to collect self-reported, anonymous data from people who have opted to participate in entheogen therapy centers and retreats during the last five (5) years on the topics of their initial intentions, motivations, experiences, demographics, and willingness to participate in future entheogen research.
Status: Recruiting
Start date: 2022-03-01
Not Applicable
Open
100 participants
Observational
A Multi-Center, Phase II, Randomized, Double-Blind, Prospective, Active Placebo-Controlled Trial of Sub-Anesthetic Intravenous Infusion of Ketamine to Treat Levodopa-Induced Dyskinesia in Subjects with Parkinson's Disease.
Status: Enrolling by invitation
Start date: 2021-10-5
Open
Interventional
Find Psychedelic Trials
Browse through all psychedelic trials that have been done or are ongoing. These trials, usually double-blind, placebo-controlled studies, are the core of psychedelic research. The outcome of these trials will determine the future of psychedelics as medicine.
The trials included in our database come from ClinicalTrials.Gov and from the various companies pursuing psychedelics as medicine. Most of the trials have been funded by universities, though companies and governments are currently starting to ramp up their involvement.
